Journal
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY
Volume 57, Issue 1, Pages 21-25Publisher
JAPANESE SOC LYMPHORETICULAR TISSUE RESEARCH
DOI: 10.3960/jslrt.17006
Keywords
PD-L1; PD-L2; Stat3; lymphoma
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology of Japan [16H05162, 16K15503]
- Grants-in-Aid for Scientific Research [16H05162, 16K15248, 17K08763, 16K09247, 16H05441, 16K15503, 17H04060] Funding Source: KAKEN
Ask authors/readers for more resources
Recent studies have indicated the significance of immune checkpoint molecules including programmed death-1 (PD-1), cytotoxic T-lymphocyte associated protein 4, and T-cell immunoglobulin and mucin domain-containing molecule-3 for anti-tumor immune responses. We previously investigated PD-1 ligand 1/2 (PD-L1/2) expression in lymphoma cell lines, and found that PD-L1/2 is expressed on the adult T-cell leukemia/lymphoma (ATL-T) and B-cell lymphoma (SLVL) cell lines. In the present study, we investigated whether the Stat3 inhibitor WP1066 abrogated PD-L1/2 expression in lymphoma cell lines. Incubation with WP1066 inhibited lymphoma cell growth and induced cell apoptosis. PD-L1/2 expression in the ATL-T, SLVL, and human brain malignant lymphoma (HKBML) cell lines was significantly abrogated by WP1066 treatment. These data indicated that a Stat3 inhibitor abrogated PD-L1/2 expression in lymphoma cells. Such an inhibitor is therefore considered to be useful for additional immunotherapy in patients with advanced lymphoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available